Antonella Ferzi
Legnano, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients.
Journal: Scientific reports
Published: April 06, 2023
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
Journal: Breast cancer research and treatment
Published: August 13, 2021
Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive/HER2 receptor-negative metastatic breast cancer: a real-world multicentre Italian study.
Journal: Therapeutic advances in medical oncology
Published: July 06, 2020
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study.
Journal: Breast (Edinburgh, Scotland)
Published: March 05, 2019
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Journal: Oncotarget
Published: January 08, 2019
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Journal: Oncotarget
Published: October 24, 2018
Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience.
Journal: Therapeutic advances in medical oncology
Published: October 05, 2018
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.
Journal: Breast care (Basel, Switzerland)
Published: July 23, 2018
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
Journal: Oncotarget
Published: April 02, 2018
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
Journal: International journal of breast cancer
Published: June 12, 2017
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
Journal: Breast (Edinburgh, Scotland)
Published: April 10, 2017
Last Updated: 09/26/2026